UW–Madison researchers have developed a safer and more efficient way to deliver a promising new method for treating cancer and liver disorders and for vaccination — including a COVID-19 vaccine that has advanced to clinical trials.
The animals are useful to researchers trying to understand SARS-CoV-2 and in the evaluation of vaccines, treatments and drugs against the disease it causes.
Researchers advise that people with symptoms avoid contact with cats, and cat owners should keep their pets indoors to limit contact with other people and animals.
Work by Brian Parks and collaborators provides a new target for understanding the genetic risk of high cholesterol, which is linked to heart disease.
Although the global surge in demand has made it more difficult in many places, WSLH’s colleagues at the university have pitched in to keep testing available in Wisconsin.
Refinement of the CoroFlu vaccine concept and testing in laboratory animal models at UW–Madison is expected to take three to six months. CoroFlu could be in human clinical trials by fall, 2020.
The cellular sleight of hand, says biomolecular chemist Feyza Engin, may also suggest ways to prevent other diseases in which the immune system targets the body’s own cells.
A UW–Madison study provides a new avenue of research for understanding and potentially preventing the development of asthma, which affects 25 million Americans.
A small amount of electricity delivered at a specific frequency to a particular point in the brain will snap a monkey out of even deep anesthesia, pointing to a circuit of brain activity key to consciousness and suggesting potential treatments for debilitating brain disorders.
Within the next few weeks, an interdisciplinary team of UW scientists hopes to begin studies of 2019-nCoV to “erect more barriers to prevent this sort of thing from happening in the future.”